Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.40 |
| ▸ | GSK3B | P49841 | 7/20 | 0.40 |
| ▸ | WNT1 | P04628 | 4/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614818 | 1.00 | ABL1 (0.47) | ABL1DYRK1AGSK3BWNT1ABL2 | |
| SCHEMBL19316713 | 0.89 | ABL1 (0.45) | ABL1DYRK1AGSK3BWNT1ABL2 | |
| SCHEMBL19316719 | 0.81 | ABL1 (0.55) | ABL1ABL2KIT | |
| SCHEMBL19307164 | 0.78 | ABL1 (0.65) | ABL1ABL2 | |
| SCHEMBL29614931 | 0.78 | ABL1 (0.65) | ABL1ABL2 | |
| SCHEMBL19307233 | 0.78 | ABL1 (0.49) | ABL1DYRK1AABL2KIT | |
| SCHEMBL29614814 | 0.78 | ABL1 (0.49) | ABL1DYRK1AABL2KIT | |
| SCHEMBL19307114 | 0.77 | ABL1 (0.48) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL29614806 | 0.77 | ABL1 (0.48) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL23732816 | 0.77 | ABL1 (0.53) | ABL1ABL2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885DYRK1A 4006/4885GSK3B 1381/4885 |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | ABL1 3590/4885DYRK1A 4111/4885GSK3B 1254/4885 |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885DYRK1A 4006/4885GSK3B 1381/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885DYRK1A 4530/4885GSK3B 2735/4885 |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | ABL1 3590/4885DYRK1A 4111/4885GSK3B 1254/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3753/4885DYRK1A 4006/4885GSK3B 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.